Oncolytic adenoviruses armed with heterologous genes
Inventors
CHAMPION, BRIAN ROBERT • BROWN, Alice Claire Noel • Fisher, Kerry David • NICOLSON, Tamara
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
Core Innovation
The invention relates to a replication competent group B oncolytic adenovirus having a defined genome architecture with an ITR-B1-BA-B2-BX-BB-BY-B3-ITR arrangement. In this architecture, B1 comprises E1A, E1B or E1A-E1B, BA comprises E2B-L1-L2-L3-E2A-L4, BB comprises L5, and B2 and B3 are bonds or comprise E3 and E4, respectively.
The core design places transgene-related elements near the L5 region using BX and BY. BX is a bond or a DNA sequence comprising a restriction site, one or more transgenes under the control of an exogenous promoter, or both, and BY comprises a transgene cassette comprising a transgene and a splice acceptor sequence, wherein the transgene cassette is under the control of an endogenous major late promoter.
The disclosed content further describes transgene cassette architectures and sequence listings for the EnAd platform, including unique restriction sites inserted in genome regions BX and BY and derived virus NG-185. The described payload categories include anti-VEGF full-length antibodies, anti-VEGF ScFvs, cytokines, tumour antigen NY-ESO-1, immune checkpoint armed viruses, sodium iodide symporter (NIS), and shRNA (GAPDH).
Claims Coverage
The independent claim defines a replication competent group B oncolytic adenovirus with a specified genome architecture, and the provided dependent claim examples refine transgene cassette expression formats, splice acceptor selections, added cassette components, variant identity, and payload specificity. Three inventive features are set out in the main claim coverage and related refinements.
Replication competent group B oncolytic adenovirus genome architecture
A replication competent group B oncolytic adenovirus comprising a sequence of formula (I): 5′ ITR-B1-BA-B2-BX-BB-BY-B3-3′ ITR, with B1 comprising E1A, E1B or E1A-E1B; BA comprising E2B-L1-L2-L3-E2A-L4; B2 a bond or comprises E3; BB comprises L5; and B3 a bond or comprises E4.
Transgene insertion near L5 using BX restriction site and exogenous promoter
BX is a bond or a DNA sequence comprising a restriction site, one or more transgenes under the control of an exogenous promoter, or both.
Transgene cassette in BY with splice acceptor under endogenous major late promoter
BY comprises a transgene cassette comprising a transgene and a splice acceptor sequence, wherein the transgene cassette is under the control of an endogenous major late promoter.
The inventive coverage centers on a replication competent group B oncolytic adenovirus with a specified ITR-B1-BA-B2-BX-BB-BY-B3-ITR genome architecture, using BX for restriction-site/exogenous-promoter transgene placement and BY for a splice-acceptor transgene cassette expressed under an endogenous major late promoter.
Stated Advantages
Preserves replication and oncolytic properties while inserting transgenes near the L5 (fibre) region.
Enables transgene expression using endogenous major late promoter control for the transgene cassette, while allowing exogenous promoter control for transgenes located in BX.
Documented Applications
Treatment of cancer using the replication competent group B oncolytic adenovirus, including use in combination therapy, and administration to a patient.
Use of the provided adenovirus constructs in vitro and in vivo where inserted transgenes can be detected, as referenced by figures/examples in the document.
Interested in licensing this patent?